Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1

ObjectivesTo present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study.MethodsThis post hoc analysis reports data from Taiwanese patients originally randomized to subcutaneous secukinumab 150 or 75mg or placebo every 4 wee...

Full description

Bibliographic Details
Main Authors: Jui-Cheng Tseng, James Cheng-Chung Wei, Atul Deodhar, Ruvie Martin, Brian Porter, Suzanne McCreddin, Zsolt Talloczy
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
biologics
interleukin-17A inhibitor
Taiwan
secukinumab
ankylosing spondylitis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.561748/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.561748/full

Similar Items